Why the study?
Heart rate variability biofeedback has been used to ameliorate depressive symptoms, but its utility for tackling depressive symptoms across comorbid adult patients is less established.
Does heart rate variability biofeedback training improve depressive symptoms and heart rate variability in adult comorbid populations compared to standard treatment?
Does heart rate variability biofeedback training improve depressive symptoms and heart rate variability in adult comorbid populations compared to standard treatment?
Heart rate variability biofeedback training is associated with improvements in both depressive symptoms and physiological heart rate variability in adults with comorbid conditions.
HRVB improves depressive symptoms and HRV in comorbid adults; extends prior evidence while correlation with HRV changes remains inconclusive.
BACKGROUND AND AIM: Heart rate variability biofeedback (HRVB) has previously been used to ameliorate depressive symptoms but its uses for tackling depressive symptoms in an array of comorbid adult patients is less established. This meta-analysis aims to evaluate whether HRVB is a useful tool to reduce depressive symptoms and improve HRV relative to standard treatment in adult comorbid populations, while also attempting to establish the association between the two outcomes. METHODS: An extensive literature review was conducted using several databases including PubMed, Cinahl, Medline, Web of science and clinical.gov/UK register. A total of 149 studies were identified with 9 studies, totalling 428 participants were analysed using a random effects model. RESULTS: Depressive outcomes yielded a mean effect size g=0.478 (CI 95% 0.212, 0.743) with HRV outcomes, yielding a mean effect size of g=0.223 (95% CI 0.036 to 0.411). Total heterogeneity was non-significant for depressive outcomes (Q= 13.77, p=0.088 I^=42.86%) and HRV (Q= 1.598, p=0.991, I^=0.000%) which indicates that little variance existed for the included studies. CONCLUSIONS: In summary, the outcomes demonstrate that HRVB can improve both clinically relevant depressive symptoms and physiological HRV outcomes in various comorbid conditions in adult populations, while the correlation between the two was moderately negative, but non-significant.
No takes yet. Share an insight, caveat, or question.
Donnelly et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: